Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
MiNK Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
8-K
| Quarterly results|
Docs:
|
"MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results NEW YORK, March 21, 2023 -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022. “2022 has been an important year for MiNK, with significant progress across our clinical and preclinical programs in iNKT cell therapy, bolstered by the expansion of our in-house manufacturing capabilities," stated Dr. Jennifer Buell, President and Chief Executive Officer of MiNK. "Our advancements have solidified MiNK's position as a leader in the iNKT cell the..." |
|
| 08/09/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
|
|